vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.8M, roughly 1.5× NextPlat Corp). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -40.2%, a 39.4% gap on every dollar of revenue. On growth, NextPlat Corp posted the faster year-over-year revenue change (-21.1% vs -25.7%). NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-15.8M). Over the past eight quarters, NextPlat Corp's revenue compounded faster (-14.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs NXPL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.8M |
| Net Profit | $-154.0K | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -6.9% | -28.9% |
| Net Margin | -0.8% | -40.2% |
| Revenue YoY | -25.7% | -21.1% |
| Net Profit YoY | 97.6% | -70.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $18.7M | $13.2M | ||
| Q1 25 | $50.9M | $14.5M | ||
| Q4 24 | $38.1M | $16.2M | ||
| Q3 24 | $33.4M | $15.4M | ||
| Q2 24 | $25.1M | $17.0M | ||
| Q1 24 | $41.5M | $17.5M |
| Q4 25 | — | $-5.1M | ||
| Q3 25 | — | $-2.2M | ||
| Q2 25 | $-154.0K | $-1.8M | ||
| Q1 25 | $23.5M | $-1.3M | ||
| Q4 24 | $18.9M | $-3.0M | ||
| Q3 24 | $5.7M | $-4.2M | ||
| Q2 24 | $-6.5M | $-5.3M | ||
| Q1 24 | $13.8M | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | — | -28.9% | ||
| Q3 25 | — | -14.5% | ||
| Q2 25 | -6.9% | -13.8% | ||
| Q1 25 | 44.4% | -10.2% | ||
| Q4 24 | 46.4% | -14.1% | ||
| Q3 24 | 12.3% | -52.1% | ||
| Q2 24 | -33.7% | -64.1% | ||
| Q1 24 | 28.1% | -10.5% |
| Q4 25 | — | -40.2% | ||
| Q3 25 | — | -15.9% | ||
| Q2 25 | -0.8% | -13.5% | ||
| Q1 25 | 46.2% | -9.2% | ||
| Q4 24 | 49.6% | -18.6% | ||
| Q3 24 | 17.2% | -27.4% | ||
| Q2 24 | -26.0% | -31.3% | ||
| Q1 24 | 33.3% | -8.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $119.9M | $17.3M |
| Total Assets | $175.1M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $13.9M | ||
| Q2 25 | $49.0M | $16.6M | ||
| Q1 25 | $47.6M | $17.7M | ||
| Q4 24 | $38.1M | $20.0M | ||
| Q3 24 | $40.6M | $20.4M | ||
| Q2 24 | $43.2M | $24.9M | ||
| Q1 24 | $36.2M | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | $119.9M | $23.5M | ||
| Q1 25 | $25.0M | $25.3M | ||
| Q4 24 | $-456.0K | $27.3M | ||
| Q3 24 | $-23.5M | $22.5M | ||
| Q2 24 | $-31.2M | $26.5M | ||
| Q1 24 | $-31.7M | $31.2M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $30.0M | ||
| Q2 25 | $175.1M | $31.0M | ||
| Q1 25 | $98.5M | $35.2M | ||
| Q4 24 | $120.5M | $37.1M | ||
| Q3 24 | $139.0M | $41.1M | ||
| Q2 24 | $159.2M | $51.5M | ||
| Q1 24 | $184.7M | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-302.0K |
| Free Cash FlowOCF − Capex | $-15.8M | $-339.0K |
| FCF MarginFCF / Revenue | -84.6% | -2.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-302.0K | ||
| Q3 25 | — | $-2.7M | ||
| Q2 25 | $-15.8M | $-1.0M | ||
| Q1 25 | $-21.0M | $-2.1M | ||
| Q4 24 | $-19.9M | $-476.0K | ||
| Q3 24 | $-20.7M | $-4.6M | ||
| Q2 24 | $-19.5M | $2.3M | ||
| Q1 24 | $-26.0M | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | $-1.1M | ||
| Q1 25 | $-21.2M | $-2.1M | ||
| Q4 24 | $-20.0M | $-508.0K | ||
| Q3 24 | $-20.7M | $-4.7M | ||
| Q2 24 | $-19.6M | $2.2M | ||
| Q1 24 | $-26.2M | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | -8.0% | ||
| Q1 25 | -41.6% | -14.3% | ||
| Q4 24 | -52.5% | -3.1% | ||
| Q3 24 | -62.1% | -30.6% | ||
| Q2 24 | -78.2% | 13.2% | ||
| Q1 24 | -63.1% | -15.7% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.2% | 0.2% | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.3% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
